Patent ID: 7642268

Claim:
A pharmaceutical composition, comprising crystalline tiotropium bromide micronisate characterised by a particle size X 50 of between 1.0 μm and 3.5 μm at a Q (5.8) value of more than 60%, by a specific surface value in the range between 2 m 2 /g and 5 m 2 /g, by a specific heat of solution of more than 65 Ws/g and by a water content from about 1% to about 4.5%, wherein the crystalline tiotropium bromide micronisate is obtained from crystalline tiotropium bromide monohydrate, which crystalline tiotropium bromide monohydrate when thermally analysed by DSC has an endothermic maximum at 230±5° C. at a heating rate of 10K/min, has an IR spectrum which has bands inter alia at wavelengths 3570, 3410, 3105, 1730, 1260, 1035 and 720 cm −1 and which is characterised by a simple monoclinic cell with the following dimensions: a=18.0774 Å, b=11.9711 Å, c=9.9321 Å, β=102.691°, V =2096.96 Å 3 ; in admixture with at least one physiologically acceptable excipient.